Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (NYSE: IQV) is frequently in the news as a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. News coverage about IQVIA highlights how the company combines high-quality health data, Healthcare-grade AI®, advanced analytics and technology to support clinical development and commercial decision-making.
On this page, readers can follow IQVIA news related to clinical research initiatives, technology launches and strategic partnerships. Recent announcements include a strategic collaboration with Amazon Web Services, under which AWS has been named IQVIA’s Preferred Agentic Cloud Provider to power a next-generation AI platform. Other news items describe the launch of IQVIA’s Clinical Trial Financial Suite, an AI-enabled platform for managing financial aspects of clinical trials, and partnerships with organizations such as Veeva Systems.
IQVIA news also covers topics such as quarterly financial results, leadership and board changes, awards for site relationships in clinical research and the expansion of clinical research networks. For example, the company reports on its Research & Development Solutions bookings and backlog, as well as its recognition with the WCG Pinnacle Award for Site Relationships in Professionalism and Communication.
Investors, researchers and industry professionals can use this news feed to monitor developments in IQVIA’s clinical research services, healthcare analytics capabilities, AI initiatives and collaborations across the life sciences ecosystem. Regularly reviewing IQVIA news can provide insight into how the company is applying data, analytics and technology to support the development and commercialization of medical treatments.
IQVIA Holdings Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $3,737 million, GAAP Net Income of $288 million, and Adjusted EBITDA of $862 million. The company's First-Quarter 2024 Operating Results showed revenue growth of 2.3% on a reported basis and 2.9% at constant currency. R&D Solutions revenue increased by 3.4%, Technology & Analytics Solutions revenue grew by 0.6%, and Contract Sales & Medical Solutions revenue rose by 3.8%. The company's contracted backlog reached $30.1 billion, up 7.9% year-over-year. IQVIA reaffirmed its full-year guidance for 2024, expecting revenue growth of 2.3% to 3.9% and Adjusted Diluted EPS growth of 7.4% to 10.3% year-over-year.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.